kotak-logo
Anthem Biosciences  Share Price

Anthem Biosciences Share Price

663.2
-4.55 (-0.68%)
ANTHEM • 06 Mar, 2026 | 03:29 PM
Buywith MTF at 3.33x leverage

Anthem Biosciences Stock Performance

1W Return-5.43
1Y Return0.00
Today's Low650
Prev. Close667.75
Mkt Cap (Cr.)37,252.86
1M Return1.58
3Y Return0.00
52-Week High873.5
Open663.80
PE Ratio63.87
6M Return-20.08
Today's High672.7
52-Week Low579.15
Face Value2

Anthem Biosciences Company background

Founded in: 2006
Anthem Biosciences Limited was originally incorporated as Anthem Biosciences Private Limited, dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to Anthem Biosciences Limited and a Certificate of Incorporation was issued by RoC on December 10, 2024.The Company has been set up as a Life sciences/ Biotechnology based venture specialising in the manufacture of catalytic preparation, other organic compounds such as speciality organic molecules, biologically active peptides etc., which are highvalue products used in drug, agrochemical and speciality chemicals industries.The Company started operations at Unit I and set up a Custom Synthesis Plant with a capacity of 6 KL in year 2007. It commenced discovery biology services with a fermentation capacity of 2 KL in 2008. It expanded the Custom Synthesis Plant at Unit I increasing its capacity from 6 KL to 24 KL in 2010. It set up a high potent lab at Unit I Bommasandra Facility in 2016. The Company was merged with Anthem Cellutions (India) Private Limited by acquiring 100% of its share capital in November, 2017. It set up a flow chemistry lab scale and solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1. It commenced operations of the Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL in 201819. In year 2020, Company started operations to biological unit 2 earmarked for a specific client. It expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL. In FY 2024, Company set up a wholly owned subsidiary Neoanthem Lifesciences Private Limited and commenced operations at Unit III for development in projects. Company launched the initial public offering of 59,575,319 equity shares of face value of Rs 2 each by raising funds through offer for sale aggregating to Rs 3395 Crore in July, 2025. The Company expanded the fermentation capacity to 140 KL at the Unit II in 2025.

Anthem Biosciences Financial Highlights


For the full year FY2025–2026, revenue reached ₹1930.28 crore and profit touched at ₹451.26 crore. As of Dec '25, Anthem Biosciences’s market capitalisation stood at ₹37,252.86 crores. Shareholding as of Dec '25 shows promoters holding 74.7%, with FIIs at 1.4%, DIIs at 7.6%, and public at 16.3%.

Anthem Biosciences Share Price Today


As of 7 Mar 2026, Anthem Biosciences share price is ₹663.2. The stock opened at ₹663.8 and had closed at ₹667.8 the previous day. During today’s trading session, Anthem Biosciences share price moved between ₹650.00 and ₹672.70, with an average price for the day of ₹661.35. Over the last 52 weeks, the stock has recorded a low of ₹579.15 and a high of ₹873.50. In terms of performance, Anthem Biosciences share price has declined by 20.1% over the past six months and has declined by 8.57% over the last year.
Read More
View details of Market Depth

Anthem Biosciences Fundamental

Market Cap (in crs)

37,252.86

Face Value

2

Turnover (in lacs)

711.47

Key Metrics

Qtr Change %
1.3
Dividend yield 1yr %
0

Anthem Biosciences Key Financials

View more
Loading chart...
Anthem Biosciences Quarterly Revenue
Anthem Biosciences Yearly Revenue
Anthem Biosciences Quarterly Net Profit/Loss
Anthem Biosciences Yearly Net Profit/Loss

Anthem Biosciences Result Highlights

  • Anthem Biosciences Ltd reported a 23.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 12.5%.

  • Its expenses for the quarter were down by 18.4% QoQ and 16.7% YoY.

  • The net profit decreased 46.5% QoQ and decreased 25.3% YoY.

  • The earnings per share (EPS) of Anthem Biosciences Ltd stood at 1.64 during Q3 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Anthem Biosciences Technical Analysis

Moving Averages Analysis
663.2
Current Price
Bullish Moving Averages
2
Bearish Moving Averages
12
Day EMA5
674.40
Day EMA10
680.20
Day EMA12
680.20
Day EMA20
675.40
Day EMA26
671.20
Day EMA50
665.00
Day EMA100
685.70
EMA
Delivery & Volume
Loading chart...

Day

57.00%

Week

69.50%

Month

57.50%

Delivery & Volume

661.97
Pivot
Resistance
First Resistance
673.93
Second Resistance
684.67
Third Resistance
696.63
Support
First Support
651.23
Second support
639.27
Third Support
628.53
Relative Strength Index
46.73
Money Flow Index
42.73
MACD
8.98
MACD Signal
13.92
Average True Range
22.27
Average Directional Index
32.83
Rate of Change (21)
9.57
Rate of Change (125)
-21.42
Compare

Anthem Biosciences Shareholding Pattern

Promoter
74.7%
Foreign Institutions
1.4%
Mutual Funds
6.9%
Domestic Institutions
7.6%
Public
16.3%

Anthem Biosciences Latest News

23 FEB 2026 | Monday
09 FEB 2026 | Monday
06 FEB 2026 | Friday

Please be aware that Anthem Biosciences stock prices are subject to continuous fluctuations due to various factors.